Hormesis, non-linearity, and risk communication

Human and Experimental Toxicology

Volumn 28, Issue 1, 2009, Pages 5-6

  Calabrese, E J ^a,b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Biphasic; Hormesis; Hormetic; Non linearity; U shaped

Indexed keywords

ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; NEUROPROTECTIVE AGENT;

ACCURACY; ARTICLE; BIOASSAY; CANCER RISK; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HORMESIS; INTERPERSONAL COMMUNICATION; NONLINEAR SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

COMMUNICATION; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; RISK ASSESSMENT; RISK MANAGEMENT; TOXICITY TESTS; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY; UNITED STATES FOOD AND DRUG ADMINISTRATION; XENOBIOTICS;

EID: 65449164290     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327109103586     Document Type: Article

References (16)

1. Calabrese EJ., Baldwin LA.,. The frequency of U-shaped dose-responses in the toxicological literature. Tox Sci 2001 ; 62: 330 - 338.
2. Calabrese EJ., Baldwin LA.,. The hormetic dose response model is more common than the threshold model in toxicology. Tox Sci 2003 ; 71: 246 - 250.
3. Calabrese EJ., Staudenmayer JW., Stanek EJ., Hoffmann GR.,. Hormesis outperforms threshold model in NCI anti-tumor drug screening data. Tox Sci 2006 ; 94: 368 - 378.
4. Calabrese EJ., Staudenmayer JW., Stanek EJ.,. Drug development and hormesis: changing conceptual understanding of the dose response creates new challenges and opportunities for more effective drugs. Curr Opin Drug Discov Devel 2006 ; 9: 117 - 123. (Pubitemid 43099081)
5. Calabrese EJ., Stanek EJ., Nascarella MA., Hoffmann GR.,. Hormesis predicts low-dose responses better than threshold models. Int J Toxicol 2008 ; 27: 369 - 378. (Pubitemid 352767915)
6. Calabrese EJ.,. An assessment of anxiolytic drug screening tests: hormetic dose responses predominate. Crit Rev Toxicol 2008 ; 38: 489 - 542.
7. Calabrese EJ.,. Modulation of the epileptic seizure threshold: implications of biphasic dose responses. Crit Rev Toxicol 2008 ; 38: 543 - 556.
8. Calabrese EJ.,. Alzheimer's disease drugs: an application of the hormetic dose-response model. Crit Rev Toxicol 2008 ; 38: 419 - 452.
9. Calabrese EJ.,. Dose-response features of neuroprotective agents: an integrative summary. Crit Rev Toxicol 2008 ; 38: 253 - 348.
10. Calabrese EJ.,. Pharmacological enhancement of neuronal survival. Crit Rev Toxicol 2008 ; 38: 349 - 390.
11. Calabrese EJ.,. Enhancing and regulating neurite outgrowth. Crit Rev Toxicol 2008 ; 38: 391 - 418.
12. Calabrese EJ.,. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. Crit Rev Toxicol 2008 ; 38: 557 - 577.
13. Calabrese EJ.,. Hormesis and medicine. Br J Clin Pharmacol 2008 ; 66: 594 - 617.
14. Calabrese EJ., Blain R.,. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol Appl Pharmacol 2005 ; 202: 289 - 301. (Pubitemid 40164282)
15. Calabrese EJ., Blain RB.,. Hormesis and plant biology. Environ Pollut 2009 ; 157: 42 - 48.
16. Bruce RD., Carlton WW., Ferber KH., Hughes DH., Quast JF., Salsburg DS.,. Re-examination of the ED01 study why the society of toxicology became involved. Fundam Appl Toxicol 1981 ; 1: 26 - 128.